Who to call at Keros Therapeutics, Inc., and when
Fundz watches for the moments Keros Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Keros Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Keros Therapeutics, Inc., from your own LinkedIn network
Keros Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
kerostx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Keros Therapeutics announced a $20 million development milestone payment from Takeda Pharmaceuticals triggered by the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept in myelofibrosis patients, marking significant progress in their collaboration.
Key Takeaways
Keros received a $20 million milestone payment from Takeda upon first patient dosing in Phase 3 ELRiSE MF trial
The trial evaluates elritercept versus placebo in myelofibrosis and anemia patients on ruxolitinib therapy
1 more takeaway
Related Filings (5)
5 more filings from Keros Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Keros Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.